PSO’s CONFERENCE

PRESENTATION BY

BANWARI NAGAR

KOTA

01/04/
2024
 KEY ACHIEVMENTS OF 2023 -24

1. Do Maximum pob

2.Regular visit with Doctor

3.Regular visit with chemist

4.Conduct DAW & NPDC

5 Do RCPA & Regular reminder to Doctor

 2023 - 24 PERFORMANCE

ACTUAL TARGET ACTUAL

% To Cum. Gr. %
PERIOD 2022-23 2023-24 2023-24
Target
(Rs. LAKH) (Rs. LAKH) (Rs. LAKH)

11.36 10.49 12.16 116 7

1st QTR.

7.66 11.42 11.71 102 52

2nd QTR.

8.01 10.38 8.99 87 12

3rdQTR.

6.74 9.70 9.83 101 45

4th QTR

33.78 41.99 42.68 102 26

TOTAL YEAR
WORK PERFORMANCE REVIEW - JAN & FEB 2024

NO. OF SEs
PARAMETER
JAN FEB
A. Doctor Coverage
> 96%
92 - 96%
< 92%

B. Doctor Call Avg.

14 & more
12 - 13
11 & less

C. Last week sales

35% or less
36% - 44%
45% & above
 MAJOR BRAND PERFORMANCE
2023 – 24

Quarterly YPM (Rs._L)

Cum. Gth
Brand / Group
%
I II III IV

ANTI-DIABETIC .27 .23 .19 .19 -20

MEFTAL GROUP 9.38 7.44 5.73 5.82 33

TUSQ GROUP .94 2.55 2.06 2.68 0

BLUMOX CA .04 0 0 .01 66

EXTACEF O/I .11 .13 .02 .04 1400

DICLOTAL GROUP 1.10 .97 .65 .95 54

OTHERS .43 .47 .37 .34 -15

TOTAL 12.27 11.79 9.02 10.02 23

 TERRITORY SALES COMMITMENT
2024 -2025

2023-24 2024-25 Commitment

2024-25 Cum.
Actual Commitment as % To
Target Rs. L Gr. %
Rs. L Rs. L Target

APR 3.75 4.19 4.25 101 13

MAY 4.25 4.00 4.50 106 6

JUN 4.17 4.00 4.25 106 2

I QTR 12.16 12.14 12.75 105 5

II QTR 11.71 13.27 13.50 102 15

III QTR 8.99 12.04 12.50 104 39

IV QTR 9.83 11.26 12.00 107 22

YEAR 42.68 48.71 51.00 104 19

 MAJOR BRAND SALES COMMITMENT
April - June 2024
Ist Qtr Sales Rs. L
Cum. Gth.
%
Brand / Group
Apr May Jun

2023 2024 2023 2024 2023 2024

ANTI-DIABETIC .09 .20 .11 .20 .07 .20 122

MEFTAL GROUP 2.37 2.70 3.52 4.00 3.49 4.00 14

TUSQ GROUP .61 .80 .21 .70 .12 .70 144

BLUMOX/CA .02 .20 0 .20
.02 .20 1400
GROUP
EXTACEF O/I .06 ..10 .04 .10 .01 .10 172
DICLOTAL .23 .40 .43 .50
.44 .50 27
GROUP
OTHERS .18 .30 .12 .20 .13 .20 62

TOTAL 3.77 4.80 4.25 5.80 4.25 5.90 34